Meeting
2014 Gastrointestinal Cancers Symposium
Phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pretreated patients with metastatic colorectal cancer.
Authors
Kazuhisa Yamaguchi
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
Kazuhisa Yamaguchi , Hiroya Taniguchi , Azusa Komori , Yukiya Narita , Shiori Uegaki , Sohei Nitta , Motoo Nomura , Shigenori Kadowaki , Daisuke Takahari , Takashi Ura , Masashi Andoh , Kei Muro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
000009083
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 627)
DOI
10.1200/jco.2014.32.3_suppl.627
Abstract #
627
Poster Bd #
E18
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji
Poster
2016 ASCO Annual Meeting
Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: A multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27).
First Author: Emmanuelle Samalin
Poster
2016 ASCO Annual Meeting
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.
First Author: Yasutoshi Kuboki
Poster
2014 Gastrointestinal Cancers Symposium
A phase II trial of metformin and fluorouracil (MetFU) for patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard treatment.
First Author: Vanessa Costa Miranda